CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Carboplatin +2 moredrug
Likely dose
Nab-paclitaxel 75mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03121352
NCT03121352Phase 2Completed
CompareCT.gov

Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Case Comprehensive Cancer Center·interventional·Posted Apr 20, 2017·Updated Oct 6, 2023

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Nab-paclitaxel, and 1 other intervention for Metastatic Triple Negative Breast Cancer. Completed, enrolled 30 participants across 2 sites.

Detailed Summary

The purpose of this study is to see how effective the combination of the two chemotherapy drugs (carboplatin and nab-paclitaxel) are when added to a third drug, pembrolizumab. Pembrolizumab is an investigational (experimental) drug that works by reinvigorating the immune system, allowing it to target and destroy cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA) for this type of breast cancer treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Triple Negative Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 20, 2017
Enrollment StartMay 19, 2017
Primary CompletionFeb 20, 2022
Study CompletionMay 23, 2022
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.2 years ago

Interventions

Carboplatindrug

AUC 4.5 IV day 1 of 21-day cycle

Nab-paclitaxeldrug

75mg/m2 IV days 1, 8 and 15 of 21-day cycle

Pembrolizumabdrug

200 mg IV every 21 days